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Tc Prolongation
nd Sudden Cardiac Death
he Association Is in the Detail*
rthur J. Moss, MD, FACC
ochester, New York
n their paper in this issue of the Journal, Straus et al. (1)
ave clarified a somewhat controversial area involving the
ssociation of QTc prolongation with the risk of sudden
ardiac death (SCD) in an adult population. Straus et al. (1)
etermined the risk relationship between QTc duration and
he probability of SCD in 6,134 subjects age 55 years and
lder who were enrolled in a prospective, population-based
otterdam study in which the average follow-up was 6.7
ears. Subjects with an abnormally prolonged QTc interval
ad a more than three-fold increased risk for SCD after
djustment for relevant covariates.
See page 362
Why the controversy? In brief, good-quality epidemio-
ogic studies investigating the QTc-risk question have come
p with different results regarding the mortality risk posed
y QTc prolongation in a general population. For example,
he Framingham study was unable to demonstrate an
ssociation of baseline QTc prolongation with total mortal-
ty or sudden death (2), yet positive findings have been
eported in the longitudinal Zutphen study from the Neth-
rlands involving middle-aged and elderly men (3), in the
trong Heart Study that enrolled American Indians (4), and
n the Cardiovascular Health Study involving community-
welling elderly subjects (5). The negative Framingham
tudy is of particular concern because it is well appreciated
hat the Framingham investigators have consistently pro-
ided excellent scientific studies. In brief, why is the
ramingham study different from all other studies or, better
till, why the difference between the Rotterdam study and
he Framingham study? Both were population-based stud-
es, with the Rotterdam study involving men and women
ge 55 years and older who were followed on average for
ore than 6 years, whereas the Framingham study involved
ubjects ages 30 to 65 years at entry into the study in 1948
ith follow-up extending over a 30-year period. This
mportant design difference in the two studies may explain
good portion of the discrepant results. In the Framingham
tudy, the baseline electrocardiogram (ECG) was recorded
*Editorials published in the Journal of the American College of Cardiology reflect the
iews of the authors and do not necessarily represent the views of JACC or the
merican College of Cardiology.o
From the Cardiology Division of the Department of Medicine, University of
ochester Medical Center, Rochester, New York.n a majority of the subjects at a relatively young age,
robably before the development of subclinical cardiac
isease; the Rotterdam study recorded the first of two
aseline ECGs when the subjects were enrolled in the study
t age 55 years, an age when subclinical cardiac disease is
ikely to be present in many of the subjects.
There are some important details in the categorized QTc
nterval cutoffs used in the Straus et al. (1) study that
arrant specific attention. Straus et al. (1) subdivided the
azett-corrected QTc interval into gender-specific group-
ngs for women and men and further subdivided the QTc
nterval into normal, borderline, and prolonged categories.
heir QTc classification approach is essentially identical to
he classification that we developed in 1992 (6) and that was
ubsequently adopted as part of the European Guidelines on
T Interval Prolongation (7). Using this approach, the
otterdam investigators were able to show a dose-response
ffect between the duration of the QTc interval (borderline
nd abnormally prolonged categories relative to normal
Tc duration) and the risk of SCD in the entire population
n two age groups (55 to 68 years and 68 years) and
eparately for men and women after adjustment for relevant
ovariates. This dose-response effect adds considerable
trength and significance to the association of QTc prolon-
ation and the risk of SCD in older adults.
What are some of the possible mechanisms for the
bserved risk association? The simplest explanation is that
Tc prolongation, whatever the cause, is proarrhythmic,
nd this alone contributes to an increased probability of
rrhythmic SCD. It is possible that the length of the QTc
nterval is just a marker for the severity of underlying
ubclinical cardiac disease (coronary, hypertension, non-
schemic cardiomyopathy, and so forth) and that the risk is
elated to the latent underlying cardiac problem. The
uthors tried to adjust for some of the relevant covariate risk
actors, but, as in any observational study, adjustment is
ever complete. Could the QTc prolongation in a general
dult population reflect genetic variability, with the in-
reased risk for SCD being a direct consequence of gene-
elated, modest QTc prolongation? It is possible that the
resence of one or more ion-channel gene polymorphisms
ould cause minor alterations in ion-channel function that
ontributes to modest prolongation in cardiac repolarization
nd an increased probability for fatal arrhythmias. For
xample, a D85N polymorphism in the KCNE1 gene, the
eta-subunit of the IKs, has been associated with drug-
nduced QTc prolongation (8). The frequency of this
olymorphism is approximately 2% to 3% in the general
opulation. In vitro cellular expression studies have substan-
iated the functional effect of this polymorphism on ven-
ricular repolarization. Alone, this polymorphism might
ave only negligible effects on the QTc duration in a general
opulation. However, the presence of additional unrecog-
ized ion-channel polymorphisms may have additive effects
n the QTc duration such that individuals who carry several
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January 17, 2006:368–9 Editorial Commentf these polymorphisms, as postulated in the carriership
odel (9), might be at increased risk for SCD. Such
olymorphisms are being investigated as modifier genes to
xplain the normal variation in the QTc interval that exists
mong overtly healthy individuals (10).
In summary, the Rotterdam group has enhanced our
nderstanding of the relationship between QTc duration
nd the risk of SCD in older adults. The question is
hether this well-crafted risk-stratification study can be
ranslated into effective management strategies to reduce
CD and improve survival in subjects with prolonged
entricular repolarization.
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